About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Friday, May 16th, 2014

The QualityStocks
Daily Stock List


Liberty Star Uranium & Metals Corp. (LBSR)

Agoracom, Pumps and Dumps, Stock Analyzer, PennyStocks24, Information Solutions Group, OurHotStockTips, and Xtremepicks reported earlier on Liberty Star Uranium & Metals Corp. (LBSR), and we report on the Company today, here at the QualityStocks Daily Newsletter.

Liberty Star Uranium & Metals Corp. is a mineral exploration company engaged in the acquisition and exploration of mineral properties in Arizona and Alaska. Currently, the Company controls properties totaling approximately 26,011 acres (roughly 41 square miles) situated over what its Management considers some of North America’s richest mineralized areas for copper, gold, silver, molybdenum (moly), and uranium. Liberty Star Uranium & Metals is headquartered in Tucson, Arizona. The Company’s shares trade on the OTCQB.

The Company’s projects include the Tombstone Super Project (TSP). This project initially consisted of 33 unpatented federal lode mining claims over a projected covered porphyry copper mineral center in southeast Arizona. In 2011 and 2012 more U.S. Bureau of Land Management (BLM) claims and Arizona Mining Exploration Permits were added. The Tombstone Super Project (TSP) hosts Liberty Star’s premier multi target property: Hay Mountain.

The Company maintains claims on two other claim blocks in Arizona: The East Silver Bell Porphyry Copper Project and the North Pipes Super Project. Additionally, via its wholly owned subsidiary, Big Chunk Corp., Liberty Star holds claims to the Big Chunk Super Project (BCSP) in Alaska.

Earlier this week, Liberty Star announced that it signed a final settlement agreement and release of all claims on the Big Chunk Property, Alaska. It announced that a final settlement agreement and release of all claims was signed by Liberty Star and Northern Dynasty Minerals Ltd. including its subsidiary/affiliate U-5 Resources Inc. Northern Dynasty releases Liberty Star from all claims.

Yesterday, Liberty Star announced that Company CEO/Chief Geologist Mr. Jim Briscoe is scheduled to visit Saudi Arabia leaving May 23 and returning June 1. The invitation for the Saudi Arabia visit was extended by “naseba” to Liberty Star subsequent to Mr. Briscoe’s visit to China with naseba in October 2013 (NR 166). The event was requested by naseba specifically for their Saudi clients, with the purpose to present Liberty Star’s Hay Mountain Project in combination, at the Saudis’ request, with a unique educational program to train and mentor young qualified geoscientists from Saudi Arabia in the art and science of Mine Finding.

Liberty Star Uranium & Metals Corp. (LBSR), closed Friday's trading session at $0.016, down 15.79%, on 3,747,142 volume with 70 trades. The average volume for the last 60 days is 1,369,040 and the stock's 52-week low/high is $0.007/$0.041.

Hitor Group, Inc. (HITR)

PennyStocks24, SmallCapStockPlays, Penny Stock Rumble, and Global Equity Report reported previously on Hitor Group, Inc. (HITR), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

Hitor Group, Inc. is an Environmental Technology Accelerator whose shares trade on the OTC Markets’ OTCQB. The Company delivers best-in-class ‘green’ technology solutions. Hitor Group applies capital and effective business practices to integrate green technologies, expand distribution channels, as well as bring about swift and profitable growth. The Company previously went by the name Nano Jet Corp. It changed its name to Hitor Group, Inc. in December of 2007. Hitor Group has its headquarters in Kirkland, Washington.

The Hitor team averages 30-plus years of experience in developing and marketing disruptive technologies. This includes communications, transportation, construction, recycling, and green technologies. The Company’s team has wide-ranging transportation, construction, and development related experience and global businesses development and negotiating with foreign governments.

Hitor areas of operation are Wind Turbines, Nano Technology, 3D Panels, Pre-Fabricated, Construction, and Water Reclamation. Regarding Wind Turbines, the Company is setting up the first of numerous manufacturing plants to manufacture an assortment of wind turbine solutions. Hitor is working closely with some of the largest steel and turbine companies in Europe to custom manufacture these turbines.

Pertaining to Nano Technology, Hitor is completing a Joint Venture Agreement with a Nano Technology partner that has created a patented process. This particular process produces new construction products from recycled tires. In addition, Hitor has developed a Joint Venture Agreement working with New Future Building utilizing a proprietary process employing pre-fabricated steel and concrete building solutions to build multifamily homes around the world.

Furthermore, Hitor Construction has an association with Garcia Contracting to complement current construction technologies. Garcia are construction experts having used the latest available technologies including 3D, G Panel, as well as recycled products. Hitor Construction engages in building high quality, durable low cost houses.

Concerning Water Reclamation, Hitor has evaluated a number of diverse technologies. The Company has chosen to partner with a manufacturer of the leading patented water filtration systems in the world that uses no chemicals at all. Hitor signed a joint venture agreement for white labeling a private patented water filtration system. This system can produce quality approved water from almost any contaminated water source.

Hitor Group, Inc. (HITR), closed Friday's trading session at $0.045, up 243.51%, on 445,573 volume with 46 trades. The average volume for the last 60 days is 87,246 and the stock's 52-week low/high is $0.007/$0.095.

Advanced Medical Isotope Corp. (ADMD)

SmallCapVoice reported earlier on Advanced Medical Isotope Corp. (ADMD), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Listed on the OTCQB, Advanced Medical Isotope Corp. engages in the production and distribution of medical isotopes. Medical isotopes (radioisotopes) are used in molecular imaging, therapy, and nuclear medicine to diagnose, manage, and treat diseases. The Company’s team consists of radio-chemists, scientists, and engineers. Advanced Medical Isotope is engaging in the development, production, and distribution of medical isotopes focused on yttrium-90 brachytherapy devices.

The Company is developing medical isotope technologies, which are changing the practice of medicine and transforming the standard of medical care. Its goal is to empower physicians, medical researchers, and ultimately, patients, through providing them with vital medical isotopes to detect, manage, and cure human disease, and improve the lives of patients.
Advanced Medical Isotope’s team collaborates with national labs and universities to implement proprietary technologies capable of producing essential medical isotopes on U.S. soil.  The Company employs creative production methods to offer a wide variety of reliable, domestically produced medical isotopes and in vivo delivery systems. The specific isotopes required are in short supply and must be created. The most common radioisotope used in diagnosis is technetium-99.

Advanced Medical Isotope employs a proton linear accelerator (PULSAR®) manufactured by AccSys Technology, Inc. The Company has targeted this compact isotope production system as its first differentiated technology. Its medical isotope products include stable isotopes, radio pharmaceuticals, and radio chemicals. Future isotopes include Indium-111; Iodine-124; Strontium-82/Rubidium-82 generators; Germanium-68/Gallium-68 generators, and Actinium-225/Bismuth-213 generators.

In February 2014, Advanced Medical Isotope announced that it received a response from the Food and Drug Administration (FDA) to its pre-market notification to the FDA pursuant to Section 510(k) of the U.S. Food, Drug and Cosmetic Act for its Yttrium-90 (Y-90) RadioGel™ patented brachytherapy cancer product. The FDA previously advised the Company that it would review the product as a medical device.

The FDA has further advised the Company that it has determined that the product is classified by statute as a Class III medical device, unless the device is reclassified. Advanced Medical Isotope’s intention is to work with the FDA to seek such reclassification, unless the additional steps required for approval of this product as a Class III medical device are more efficient.  The Company has obtained input from the FDA concerning its alternatives and will seek further input to accelerate the process.

Advanced Medical Isotope Corp. (ADMD), closed Friday's trading session at $0.0318, down 3.64%, on 486,547 volume with 18 trades. The average volume for the last 60 days is 456,826 and the stock's 52-week low/high is $0.0212/$0.125.

Baltia Air Lines, Inc. (BLTA)

PennyStocks24, StockHideout, Stock Roach, PennyStockSpy, and 007 Stock Chat reported earlier on Baltia Air Lines, Inc. (BLTA), and today we choose to report on the Company, here at the QualityStocks Daily Newsletter.

Baltia Air Lines, Inc. is a U.S. start-up airline based at John F. Kennedy International Airport, Jamaica, New York. The Company’s service is subject to receipt of government operating authority, and as such, no ticket sales are currently available. Baltia Air Lines is the only Part 121 (heavy jet operator) start-up airline in the United States today that has received Government fitness approval. Baltia Air Lines is preparing to operate the only non-stop flights for passengers, cargo, and mail from New York's JFK International Airport to Pulkovo Airport in St. Petersburg, Russia.  The Company’s shares trade on the OTCQB.

Baltia Air Line’s goal is to become the foremost U.S. airline in the trans-Atlantic market between the major U.S. cities and capital cities of Eastern Europe. This includes Russia, Latvia, Ukraine, and Belarus. The Company’s plan is to provide First, Business, and Voyager Class accommodations. Baltia’s intention is to provide this high quality three-class passenger service, as well as reliable cargo and mail transportation.

Baltia Air Lines plans to begin its foreign scheduled air transportation as the only U.S. airline, connecting directly, to two of the world's most prominent cities - New York, New York and St. Petersburg, Russia. Baltia has identified many market segments in the U.S.-Russia market. These are Business Travelers, General Tourism, Ethnic Travelers, Special Interest Groups, Professional Exchanges, and Government and Diplomatic Travel. Baltia has passenger service and ground service arrangements at JFK and at Pulkovo Airport in St. Petersburg.

In the third quarter of 2012, Baltia Air Lines opened an office/base of operations at Willow Run Airport in Ypsilanti, Michigan. This location will serve as its operations control center. At the Ypsilanti location, an aircraft maintenance contractor will complete major aircraft maintenance on a contract basis.

Baltia Air Lines announced in November 2013 the start of training for the Company’s initial squad of pilots. The course consisted of non-aircraft specific courses, aircraft specific courses, and simulator sessions.  Baltia's flight crew training is a significant milestone for the Willow Run-based start-up airline. The pilot training is at a certified state-of-the-art airline training facility in Ypsilanti.

Baltia Air Lines is selecting experienced cabin crew personnel in preparation for the Company’s inaugural flight. Last month, Baltia Air Lines announced that its B747 aircraft has entered scheduled maintenance inspection in preparation for its operations. At present, Baltia is in an advanced stage of the FAA Air Carrier Certification process. The Company expects to commence revenue generating flights this calendar year.

Baltia Air Lines, Inc. (BLTA), closed Friday's trading session at $0.0109, down 0.91%, on 1,962,628 volume with 63 trades. The average volume for the last 60 days is 4,762,102 and the stock's 52-week low/high is $0.0083/$0.041.

New Colombia Resources, Inc. (NEWC)

Financial News Media and Financial Markets reported previously on New Colombia Resources, Inc. (NEWC), and we highlight the Company today, here at the QualityStocks Daily Newsletter.

New Colombia Resources, Inc. focuses on the acquisition and development of high-quality metallurgical coal properties and other available resources in the Republic of Colombia. The Company expects to have three revenue producing businesses. These are metallurgical coal mining, African palm distribution, and traditional and organic coffees. New Colombia Resources has its headquarters in Florida. The Company lists on the OTC Markets’ OTCQB.

New Colombia Resources owns 100 percent of the La Tabaquera metallurgical coal mine in Colombia with an estimated 15-17 MM tonnes of reserves. The Company has another pending acquisition for 390 ha and a solicitation contract for 184 ha metallurgical coal concession.

This month, it is planting 3,000 African palm trees to use as a showcase for a seedling and fertilizer distribution business. Upon obtaining the necessary financing, New Colombia’s intention is to have additional revenue producing business units in Colombia. This includes coal mining, coking oven facilities, docks, river, and rail transportation to export terminals in Colombia. The Company’s plan is to sell its coal at the mine's gate unless it enters into off-take agreements. When feasible, New Colombia Resources plans to build or acquire river or rail loading facilities on the Magdalena River close to its mines.

In January 2014, New Colombia Resources announced that it closed the acquisition of Café Tolima Don Diego, LLC (Café Tolima) from Diego Guarnizo. The Company made this acquisition to distribute USDA Certified Organic Coffee in Colombia, North America, Europe, and China. This acquisition is in line with New Colombia Resources’ corporate goal of leveraging resource opportunities in the Republic of Colombia. 

Last week, New Colombia Resources announced an agreement of collaboration with the Phoenix Tears Foundation. This agreement is for the research and development of a cannabis based medicine to treat skin cancer in Colombia. 

Yesterday, New Colombia Resources announced an agreement of collaboration with Farmatech S.A. (Medellin, Colombia) for the research and development of topical cannabis based medicines to treat skin cancer and other ailments in Colombia. Farmatech S.A. is a pharmaceutical laboratory. It collaborates with private companies, universities, institutions, and NGOs. New Colombia Resources is in discussions with Cannabis Science, Inc. (CBIS) to oversee research in Colombia upon the establishment of protocols by Farmatech S.A.

New Colombia Resources, Inc. (NEWC), closed Friday's trading session at $0.0164, down 0.61%, on 497,160 volume with 22 trades. The average volume for the last 60 days is 199,075 and the stock's 52-week low/high is $0.0115/$0.049.


The QualityStocks
Company Corner


Armco Metals Holdings, Inc. (AMCO)

The QualityStocks Daily Newsletter would like to spotlight Armco Metals Holdings, Inc. (AMCO). Today, Armco Metals Holdings, Inc. closed trading at $0.24, off by 7.62%, on 239,531 volume with 212 trades. The stock’s average daily volume over the past 60 days is 551,218, and its 52-week low/high is $0.18/$0.58.

Armco Metals Holdings, Inc. today announced that its Armco (Lianyungang) Renewable Metals, Inc. subsidiary has entered into a steel scrap distribution agreement with TEWOO Metals International Trade Co., Ltd., the largest state-owned enterprise in Tianjin that engages in domestic and international trading, distribution, machining, delivery and E-commerce of metals and industrial commodities. Under the terms of the agreement, Renewable Metals will serve as a vendor to source, process and distribute steel scrap from TEWOO Metals, which has a registered capital of 700 million RMB and was established on May, 2006 through the merger and integration of three companies; Tianjin Metal Material Company, Tianjin Xiantong Material & Trade Co.. Ltd., and Tianjin Hopetone Co., Ltd.

Armco Metals Holdings, Inc. (AMCO), since its founding 10 years ago, has worked tirelessly to create low-cost, high-quality solutions to meet steel industry demands and achieve its goal to become the largest scrap steel recycler in China. The company operates through five subsidiaries located in key regions throughout the country to source, import, process, and distribute quality, environmentally friendly recycled scrap steel, as well as metal and non-ferrous metal ore.

Subsidiaries Armco Metals International, Ltd., Armco (Lianyungang) Renewable Metals, Inc., Armet (Lianyungang) Holdings, Inc., Henan Armco & Metawise Trading Co., Ltd., Armco Metals (Shanghai) Holding, Ltd. support Armco Metal’s overarching corporate mission and operate to provide the country’s steel production industry with sustainable, responsible solutions to its material needs. Aligned with China’s green initiatives, Armco Metals and its subsidiaries are helping the government reach its scrap metal consumption goal of 20% by 2015.

Leveraging long-standing relationships with more than 10 international metal suppliers, more than 100 small- and medium-sized Chinese steel production companies, and some of the country’s large state-run foundries, Armco Metals benefits from a steady and dependable supply of demand for the company’s high-quality product known for excellent market values.

Armco Metals’ management team has established a unique approach to business and environment by providing responsible solutions based on environmentally friendly practices; reliable, cost-effective sourcing; and quality metal products. Backed by more than 10 years of industry experience, company executives have successfully positioned the company as credible, dependable partner for customers, suppliers, and investors within the steel production market. Disclaimer

Armco Metals Holdings, Inc. Company Blog

Armco Metals Holdings, Inc. News:

Armco Metals Holdings Enters Into Scrap Steel Distribution Agreement With TEWOO Metals International Trade Co., Ltd.

Armco Metals Holdings Inc. to Host First Quarter End 2014 Earnings Conference Call on Tuesday May 20, 2014 at 5:00 p.m. EST

Armco Metals Holdings Enters Into Agreement to Acquire 100% of Draco Resources, Inc.

VistaGen Therapeutics, Inc. (VSTA)

The QualityStocks Daily Newsletter would like to spotlight VistaGen Therapeutics, Inc. (VSTA). Today, VistaGen Therapeutics, Inc. closed trading at $0.68, up 13.33%, on 29,000 volume with 9 trades. The stock’s average daily volume over the past 60 days is 4,672, and its 52-week low/high is $0.25/$0.89.

VistaGen Therapeutics, Inc. (VSTA) is a biotechnology company applying stem cell technology for drug rescue and cell therapy. Drug rescue combines human stem cell technology with modern medicinal chemistry to generate new chemical variants ("drug rescue variants") of once-promising drug candidates that have been discontinued during late-stage preclinical development due to heart or liver safety concerns. VistaGen also focuses on cell therapy, or regenerative medicine, which includes repairing, replacing or restoring damaged tissues or organs.

VistaGen's versatile stem cell technology platform, Human Clinical Trials in a Test Tube™, has been developed to provide clinically relevant predictions of potential heart and liver toxicity of promising new drug candidates long before they are ever tested on humans.

By more closely approximating human biology than conventional animal studies and other nonclinical techniques and technologies currently used in drug development, VistaGen's human stem cell-based bioassay systems can improve the predictability of the drug development cycle and lower the cost of new drug research and development by identifying product failures earlier in the cost curve.  According to the Food and Drug Administration even only a ten percent improvement in predicting failure before clinical trials could save $100 million in development costs, which savings ultimately could be passed on to patients.

Using mature human heart cells produced from stem cells, VistaGen has developed and internally validated CardioSafe 3D™, a novel three-dimensional (3D) bioassay system for predicting the in vivo cardiac effects of new drug candidates before they are tested in humans. VistaGen is now focused on using CardioSafe 3D™ to generate up to two new, safer small molecule drug rescue variants every twelve to eighteen months.  VistaGen anticipates that these drug rescue variants will be modified versions of once-promising new drug candidates that have been discontinued by pharmaceutical companies and academic research institutions because of heart toxicity concerns, despite substantial prior investment and positive efficacy data demonstrating their potential therapeutic and commercial benefits.  In most cases, VistaGen plans to license or sell its new, safer drug rescue variants in strategic partnering arrangements with global pharmaceutical companies, arrangements providing VistaGen with both near term and downstream milestone payments and economic participation rights but without future development cost obligations. 

AV-101, VistaGen's lead small molecule prodrug candidate has successfully completed Phase I clinical development in the U.S. for treatment of neuropathic pain, a serious and chronic condition affecting millions of people worldwide, depression, and other neurological diseases and conditions. To date, the U.S. National Institutes of Health (NIH) has awarded VistaGen over $8.75 million for development of AV-101. Management anticipates strategically out-licensing AV-101 to a development and marketing partner in 2013.

Neuropathic pain affects approximately 1.8 million people in the U.S. alone. Although the current active AV-101 IND is for the treatment of neuropathic pain, VistaGen's development plan and regulatory strategy for AV-101 has been designed to allow its Phase 1 safety studies to support Phase 2 development for depression, epilepsy, Huntington's Disease and Parkinson's disease, indications for which there is now supporting preclinical efficacy data.  To date, VistaGen has been awarded over $8.5 million from the U.S. National Institutes of Health (NIH) for development of AV-101.

VistaGen is also developing LiverSafe 3D™, a novel predictive liver toxicity and drug metabolism bioassay system for drug rescue applications. In parallel with drug rescue activities, the Company is funding early-stage nonclinical studies focused on potential cell therapy applications of its Human Clinical Trials in a Test Tube™ platform. Disclaimer

VistaGen Therapeutics, Inc. Company Blog

VistaGen Therapeutics, Inc. News:

VistaGen Receives Notice of Allowance for U.S. Patent Expanding Stem Cell Technology Platform for Drug Rescue and Regenerative Medicine

VistaGen Joins the Cardiac Safety Research Consortium

VistaGen Provides Update on $36 Million Strategic Financing Agreement

WordLogic Corp. (WLGC)

The QualityStocks Daily Newsletter would like to spotlight WordLogic Corp. (WLGC). Today, WordLogic Corp. closed trading at $0.15, up 11.03%, on 151,970 volume with 11 trades. The stock’s average daily volume over the past 60 days is 83,039, and its 52-week low/high is $0.065/$0.28.

WordLogic Corp. (WLGC) leverages more than 10 years of advanced R&D to assume its position as a global leader in predictive text input technology. Backed by multiple patents and its predictive engine, WordLogic’s interface is revolutionizing the way individuals and businesses search and communicate on touch screen devices. Furthermore, WordLogic offers a range of licensing options of its technology and patent portfolio.

The company’s technology incorporates proprietary Gesturing™ and WordChunking™ features that accelerate typing speeds while reducing the effort needed for accuracy. This interface increased text input on mobile devices by five times, rapidly speeding communication via instant messaging, text messaging, captioning, email and information searching. The iKnowU® keyboard uses state-of-the-art patented technology that becomes more accurate with each use, constantly learning about the user’s style and preferences. Utilizing the WordChunking and Gesturing, iKnowU enables the user to chain together phrases and create whole sentences in a matter of seconds.

For the business realm, WordLogic has developed a unique cloud solution to fit the specific needs of multiple industry sectors, enabling enterprises to create a single cloud-based dictionary specific to the company’s realm of expertise or multiple dictionaries specific for individual specialties or departments. This cloud solution creates continuity for users across multiple devices, boosting accuracy and productivity. WordLogic Reach™ enables users to select and insert meeting plans, contact information, and calendar entries from other apps in the mobile device.

Frost & Sullivan recently recognized WordLogic as the recipient of the 2014 North American Enabling Technology Leadership Award for Predictive Keyboard Applications, saying, “WordLogic’s technically impressive product - WordLogic Predictive Engine and its associated products iKnowU® and Reach™ - offers key competitive advantages, such as market-leading word and phrase prediction capabilities, a context-aware advertising model; simpler integration, increased speed and accuracy; and reduced costs. Add to that the significant number of pending and issued patents and you can see how value a package of technology WordLogic has developed truly is.” Disclaimer

WordLogic Corp. Company Blog

WordLogic Corp. News:

WordLogic Pre-Releases Award-Winning iKnowU Keyboard With REACH™ to Interested Developers and Partners

WordLogic Corp. Announces Engagement of QualityStocks Investor Relations Services

Frost & Sullivan Applauds WordLogic for Simplifying Texting With Its Predictive Engine for Mobile Devices

P2 Solar, Inc. (PTOS)

The QualityStocks Daily Newsletter would like to spotlight P2 Solar, Inc. (PTOS). Today, P2 Solar, Inc. closed trading at $0.0498, up 24.50%, on 2,900 volume with 2 trades. The stock’s average daily volume over the past 60 days is 63,829, and its 52-week low/high is $0.0122/$0.08.

P2 Solar, Inc. (PTOS) participates in the lucrative renewable energy market as a developer of solar photovoltaic (PV) power projects, focusing its initiatives on “sunbelt” areas where sunlight exposure is abundant; renewable energy policies are favorable; public and private sectors are actively seeking to incorporate solar PV into their electricity consumption profiles; and where governments offer attractive subsidies to motivate development.

Acknowledging rising demand for clean energy worldwide, solar PV power’s increasingly competitive edge over grid electricity, and commercial efforts to reduce reliance on greenhouse gas emitting fossil fuels, P2 Solar invests and channels its resources to benefit from these global trends.

The company’s growth strategy centers on management’s aggressive mandate to develop 150 MWp of electricity generating capacity in several phases over the next few years. To this accord, the company is focused on further development of its project portfolio, which currently consists of the Langley Rooftop Project in British Columbia; the Rajgarh Mini-hydro Project in Punjab, India; and the Tibba Mini-hydro Project, also located in Punjab India.

Backed by executive leadership with more than 60 years of combined experience, P2 Solar continues to develop and expand its current projects while opportunistically pursuing development opportunities in other regions with favorable solar energy regimes, including Eastern Europe and Canada. Disclaimer

P2 Solar, Inc. Company Blog

P2 Solar, Inc. News:

P2 Solar Signs Implementation Agreement for Rajgarh Hydro Project

P2 Solar Receives Government Approval for Rajgarh Hydro Project

P2 Solar Acquires Its Second Renewable Energy Project in India

NutraNomics, Inc. (NNRX)

The QualityStocks Daily Newsletter would like to spotlight NutraNomics, Inc. (NNRX). Today, NutraNomics, Inc. closed trading at $0.0949, up 15.73%, on 5,900 volume with 3 trades. The stock’s average daily volume over the past 60 days is 262,872, and its 52-week low/high is $0.0605/$1.48.

NutraNomics, Inc. (NNRX) is focused on the research and development of nutritional dietary supplements, skin and body care products and transdermal patches. In addition to creating formulas for hundreds of companies, the company has produced and branded its own product lines which are sold through retail and wholesale channels. Additionally the company private labels and does custom manufacturing for several supplement companies in national and international markets.

Nearly all vitamins currently on the market are isolated and/or synthetic. The human body doesn’t recognize these types of vitamins and as a result cannot absorb them because they are either missing critical nutritional components or are not food based. NutraNomics has rapidly grown its business over the past 18 years by offering superior food and plant-based products blended from the highest quality sources available for maximum bioavailability.

Today NutraNomics has sales teams in seven different countries promoting its diversified line of wholefood-based supplements, specialty formulas, and remedies. All facilities used to produce the gluten-free, non-GMO nutritional products are cGMP Compliant and FDA approved. To ensure the highest purity potency and quality, the company takes it another step forward by performing additional content testing on all raw materials used to manufacture its products.

NutraNomics is more than just a health supplement provider. As a company dedicated to supporting the worldwide community of people who want to live healthy, NutraNomics is making an impact on those who are suffering from various types of diseases that need specialized diet to enhance their lifestyle. To fulfill this mission NutraNomics has invested in clinical studies for controlling diabetes, heart disease and cancer with dietary supplements. Strong growth is anticipated to continue as the company continues to introduce cutting-edge products and taps into new markets. Disclaimer

NutraNomics, Inc. Company Blog

NutraNomics, Inc. News:

Nutranomics Discusses Long-Term Global Expansion Strategy with UNO International Corp.

Nutranomics Receives Initial Purchase Order from Leading Health Products Distributor in the Philippines

Nutranomics Announces Exclusive Shareholder Product Promotion


Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters





Top Stock Picks



By The Numbers Charts

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors


The QualityStocks By The Numbers Report

Click the chart below to see the full report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.


About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251